Sign In
Buy ICCC
$10.05
+0.260 (+2.66%)
At Close: Jun 03, 2026
ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
02:00pm, Friday, 28'th Feb 2025
ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.
ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript
11:44am, Wednesday, 26'th Feb 2025
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President and
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
04:05pm, Tuesday, 25'th Feb 2025
PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
08:19am, Thursday, 20'th Feb 2025
Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET
ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses
04:05pm, Thursday, 16'th Jan 2025
PORTLAND, Maine, Jan. 16, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
04:05pm, Thursday, 09'th Jan 2025
PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
08:51am, Wednesday, 04'th Dec 2024
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential o
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
12:21pm, Tuesday, 19'th Nov 2024
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.
ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript
11:09am, Thursday, 14'th Nov 2024
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Pa
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
04:05pm, Wednesday, 13'th Nov 2024
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
08:30am, Thursday, 07'th Nov 2024
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
04:05pm, Tuesday, 08'th Oct 2024
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
04:05pm, Tuesday, 13'th Aug 2024
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
04:05pm, Wednesday, 07'th Aug 2024
Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
04:05pm, Tuesday, 09'th Jul 2024
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
